Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.

The prototype for analyzing skin aging works technically and clinically.

Microneedles could revolutionize pediatric medicine by offering painless drug delivery, but more development is needed.

Early diagnosis and treatment are crucial for CAPS, and Eculizumab can be effective.

The transtemporal midface lift improves the lower eyelid and cheek area with high patient satisfaction and low complication rates.

Icariside II may help treat gastric cancer by stopping tumor growth.

Individual choice in treating alopecia areata greatly impacts quality of life.

Ritlecitinib provides new treatment options for diverse alopecia areata patients.

Patients should discuss complementary medicine use with doctors to improve health outcomes.

A new treatment using nanoparticles can effectively prevent and reduce hair loss caused by chemotherapy.

Gender-affirming care for youth remained essential during the COVID-19 pandemic, with telemedicine playing a key role.

Eculizumab helps reduce blood transfusions and stabilize hemoglobin but increases infection risk and is expensive.

Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.

A 5-year-old girl with a rare skin disorder was effectively treated with skin creams instead of oral medication.

Proactive physical therapy improved mobility, reduced fatigue, and pain in lupus patients.

Improved care and timely diagnosis are needed for women with PCOD and PCOS, and CystaCare can help.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

Bead-jet printing of stem cells improves muscle and hair regeneration.

The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.

Various dermatology events and meetings were announced for 1998.

The decision board effectively helps lupus nephritis patients in Brazil choose treatments by clearly presenting options and side effects.

Few dermatology programs mention gender-affirming care, highlighting a need for better training and visibility.

Ritlecitinib is more effective and cost-efficient than baricitinib for severe alopecia areata.

Technology, like stem cell therapy and teledermatology, is improving dermatology care.

Infants with severe KID syndrome may be more prone to serious infections and need close monitoring.

Transgender individuals face insurance barriers to gender-affirming surgery, needing policy reforms for better access.

The document concludes that while some advocate for a patient voucher system, it may be unequal and current healthcare reforms should be given a chance, and it also recommends various medical books for their comprehensive coverage and advice on specific health issues.